Axsome Therapeutics (AXSM) vs Elanco Animal Health (ELAN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Elanco Animal Health (ELAN) over the past year, gaining 37.4% versus a gain of 14.2%. Over five years, AXSM leads with a +319.8% price change compared with -29.6% for ELAN. Elanco Animal Health is the larger company by market cap ($11.45 billion vs $8.82 billion), about 1.3 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +6.2%).
On valuation, Elanco Animal Health trades at a lower forward P/E (17.8x vs 35.8x for Axsome Therapeutics). Elanco Animal Health converts more of its revenue into profit, with a net margin of -4.9% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | ELAN |
|---|---|---|
| Share price | $168.35 | $22.92 |
| Market cap | $8.82B | $11.45B |
| 1-day change | -1.02% | +1.69% |
| YTD return | -7.82% | +1.28% |
| 1-year return | +37.41% | +14.20% |
| 5-year return | +319.83% | -29.56% |
| Forward P/E | 35.80 | 17.84 |
| EPS (TTM) | $-3.74 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $4.71B |
| Revenue growth (YoY) | +65.55% | +6.22% |
| Net income (latest FY) | $-183.17M | $-232.00M |
| Gross margin | 92.56% | 54.99% |
| Operating margin | -26.12% | — |
| Net margin | -28.69% | -4.92% |
| 52-week high | $260.19 | $27.98 |
| 52-week low | $119.20 | $19.40 |
| Distance from 52-week high | -35.30% | -18.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.07% | +35.25% |
| Average volume | 710.84K | 6.22M |
| Shares outstanding | 52.38M | 499.45M |
| Employees | 1,346 | 9,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed ELAN by 23.2 percentage points over the past year.
- Elanco Animal Health is more profitable, keeping -4.9 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +6.22%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
AXSM vs ELAN FAQ
Which is bigger, Axsome Therapeutics or Elanco Animal Health?
Elanco Animal Health (ELAN) is larger, with a market capitalization of $11.45B compared with $8.82B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or ELAN?
AXSM returned +37.41% over the past 12 months, compared with +14.20% for ELAN (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Elanco Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.